CJC-1295 for Sleep: Does It Help Deep Sleep?

Key takeaways

• No study has measured sleep in people taking CJC-1295 or ipamorelin, alone or together. The deep-sleep claim is borrowed from research on natural GHRH and ghrelin.
• In the lab, four nightly intravenous pulses of GHRH raised slow-wave sleep from 14% to 20% of the night in seven young men; the same dose given continuously had no significant effect. In older adults the effect was much smaller, and in young women GHRH reduced deep and REM sleep.
• CJC-1295 with DAC lasts about eight days and stimulates the pituitary continuously, raising the troughs between growth hormone pulses 7.5-fold: the delivery pattern that did least for sleep. The version without DAC has never been studied in humans at all.
• Ipamorelin's drug class has inconsistent sleep effects: ghrelin deepened sleep in older men but not women, GHRP-6 added only light sleep, and hexarelin reduced deep sleep.
• Neither peptide can be legally compounded in the US. For sleep, CBT-I and FDA-approved medications have the evidence; sermorelin is the GHRH analog a clinician can prescribe, but it is not a sleep treatment.

No study has measured sleep in anyone taking CJC-1295 or ipamorelin, alone or together, so there is no evidence that either improves deep sleep. The claim comes from laboratory studies of natural growth hormone-releasing hormone (GHRH), which increased slow-wave sleep when given in short pulses but not when given continuously, and the long-acting CJC-1295 with DAC delivers a continuous stimulus that lasts about a week. This guide is part of our ranking of the best peptides for sleep; DSIP dosage covers the other peptide sold for sleep, and the CJC-1295 and ipamorelin profile covers both compounds in full.

What GHRH does to deep sleep in the lab

Slow-wave sleep, the deepest stage of non-REM sleep, and the night's largest growth hormone pulse arrive together early in the night. That link is why GHRH was tested as a sleep signal, and in young men it behaves like one, under specific conditions.

Read that table with four limits in mind. Every positive result came from repeated intravenous pulses spread across the first half of the night, not one injection under the skin. The participants were healthy volunteers, not people with insomnia. The benefit shrank with age and reversed in women. And none of the studies used CJC-1295, sermorelin or any analog sold today. GHRH physiology is a reason the question is worth asking, not an answer to it.

Why CJC-1295 with DAC is the opposite of what was studied

CJC-1295 is the first 29 amino acids of GHRH with four of them swapped for stability. The common version adds a drug affinity complex (DAC) that binds the peptide to albumin in the blood, stretching its half-life to about eight days (Ionescu 2006). One injection therefore keeps stimulating the pituitary's GHRH receptors around the clock for a week or more.

What that does to growth hormone has been measured once. In healthy men aged 20 to 40, a single 60 or 90 mcg/kg injection left the number and size of growth hormone pulses unchanged a week later but raised the troughs between them 7.5-fold, lifting mean growth hormone by 46% and IGF-1 by 45% (Ionescu 2006). The pulses survive, but they sit on a raised floor, driven by a stimulus that never switches off. Nobody recorded how those men slept.

That continuous pattern is the one GHRH research found least useful for sleep. When the same total dose of GHRH was given as a steady infusion instead of four pulses, its effect on sleep was not significant (Marshall 1996). The comparison is imperfect, and it should be said plainly: that infusion lasted three and a half hours, not a week, and no one has recorded sleep during a week-long GHRH stimulus. It does not prove that CJC-1295 with DAC harms sleep. It does show that the physiology sellers cite for deep sleep is pulse physiology, and the DAC form was engineered to replace pulses of GHRH with a constant signal.

Two practical consequences follow. Bedtime timing, a fixture of clinic protocols, is irrelevant for a peptide that acts for a week. And the version without DAC, sometimes sold as modified GRF (1-29), is short-acting like natural GHRH, so it is closer to the studied pattern on paper; but it has never been tested in a published human study of any kind, and a single nightly injection under the skin is still not the four-pulse protocol that worked.

What about ipamorelin?

Ipamorelin acts on a different target, the ghrelin receptor, which is why it is paired with CJC-1295: GHRH and ghrelin push growth hormone from two directions. Ghrelin itself does promote deep sleep in some people. In 10 men and 10 postmenopausal women in their early sixties, four 50 mcg intravenous pulses of ghrelin increased slow-wave sleep in the men from about 33 to 44 minutes and total non-REM sleep from about 273 to 318 minutes, while REM sleep fell; in the women, ghrelin had no effect on sleep (Kluge 2010).

Synthetic drugs that act on the same receptor have not behaved consistently. In young men, GHRP-6 increased light stage 2 sleep without changing slow-wave sleep, and hexarelin, given in the same four-pulse pattern, decreased stage 4 sleep and deep-sleep EEG activity while raising ACTH, cortisol and prolactin (Frieboes 2004). The oral ghrelin-receptor drug MK-677, which is not a peptide, increased deep and REM sleep in a small 1997 study, as our parent guide describes. Nobody has recorded sleep in a person taking ipamorelin, so which of these patterns it follows, if any, is unknown. Nobody has studied the CJC-1295 and ipamorelin combination for sleep or for anything else.

Legal status

Neither peptide can be legally compounded in the United States in October 2026. FDA placed both in Category 2 in 2023; its advisory committee voted against ipamorelin in October 2024 and against every form of CJC-1295, with and without DAC, in December 2024; and FDA now lists both as nominated but withdrawn, which removes the safety flag without creating any basis for compounding. A prescription does not change that, and vials sold for "research use only" are unapproved drugs, a label FDA's 2026 warning letters rejected as a defense. The details are in the legal tracker and the CJC-1295 and ipamorelin profile.

What helps sleep with evidence

• Cognitive behavioral therapy for insomnia (CBT-I). The American Academy of Sleep Medicine gives multicomponent CBT-I its only strong recommendation for chronic insomnia in adults and advises against relying on sleep hygiene alone (Edinger 2021).
• Approved medication when needed. The orexin antagonists, which block the wake-promoting peptide orexin, were tested on sleep-lab recordings in trials of hundreds to nearly two thousand adults; the numbers are in our best peptides for sleep guide.
• A sleep evaluation if you snore with pauses in breathing, have restless legs or fall asleep without warning during the day. A growth hormone peptide will not treat sleep apnea.
• If what you want is a growth hormone peptide, sermorelin is the GHRH analog a licensed pharmacy can dispense: short-acting, injected at bedtime, with an FDA approval history. Be clear about what it is not. No sermorelin trial has measured sleep objectively, a GHRH-analog trial in older adults found sleep quality unchanged (see the sermorelin profile), and GHRH impaired sleep in young women (Mathias 2007). It is a treatment for documented low IGF-1, monitored with labs, not a sleep aid.

Bottom line

CJC-1295 has never been tested for sleep, and neither has ipamorelin. The physiology sellers cite comes from GHRH given in short intravenous pulses to young men, an effect that shrank with age, reversed in women, and was not significant when the same hormone was infused continuously, which is what CJC-1295 with DAC does for a week at a time. Ipamorelin's drug class has produced deeper, lighter and unchanged sleep depending on the molecule and the sex of the sleeper. Neither peptide can be legally compounded. If deep sleep is the goal, CBT-I, a sleep evaluation and approved medication have the evidence; if a growth hormone peptide is the goal, sermorelin is the legal one, and it should be prescribed for IGF-1, not for sleep.

Frequently asked questions

+−Does CJC-1295 help you sleep?

There is no evidence that it does. No study has measured sleep in people taking CJC-1295, with or without DAC. The claim is borrowed from laboratory studies in which four intravenous pulses of natural GHRH increased slow-wave sleep in young men. CJC-1295 with DAC lasts about eight days and stimulates the pituitary continuously, the delivery pattern that did not significantly change sleep when GHRH itself was infused continuously, and the no-DAC version has never been studied in humans at all.

+−Does CJC-1295 increase deep sleep or nighttime growth hormone?

It raises growth hormone, but not the way deep sleep does. A week after one injection of CJC-1295 with DAC, healthy men had growth hormone pulses of unchanged number and size sitting on troughs 7.5 times higher than before, with mean growth hormone up 46% and IGF-1 up 45%. Nobody measured their sleep. Higher growth hormone is not the same thing as more slow-wave sleep, and no study has shown that CJC-1295 changes sleep stages.

+−Does ipamorelin help with sleep?

No study has recorded sleep in anyone taking ipamorelin. It activates the ghrelin receptor, and the evidence for that receptor is mixed: ghrelin itself increased slow-wave sleep in older men but had no effect in older women, GHRP-6 increased light stage 2 sleep without changing deep sleep, and hexarelin reduced deep sleep while raising cortisol. Which pattern ipamorelin would follow is unknown, and it cannot be legally compounded in the United States.

+−Is CJC-1295 with DAC or without DAC better for sleep?

Neither has any sleep data. On paper the version without DAC, which is short-acting, is closer to the pulsed GHRH that increased deep sleep in laboratory studies, while the DAC version provides a continuous stimulus for about a week, the pattern that did least for sleep. But the no-DAC version has never been tested in a published human study for anything, so there is no evidence it works, no known dose and no safety record.

+−When should you take CJC-1295 for sleep?

There is no evidence-based timing, because there is no evidence of a sleep effect. Clinic charts say bedtime on an empty stomach, borrowing the logic of short-acting secretagogues whose growth hormone pulse coincides with early sleep. For CJC-1295 with DAC, which keeps acting for about a week, the time of injection is irrelevant. Neither form can be legally compounded in the United States, so there is no labeled product whose timing could be followed.

+−Can you take sermorelin and ipamorelin together for sleep?

Clinics sell sermorelin and ipamorelin blends on the theory that GHRH and a ghrelin-receptor agonist amplify each other's growth hormone release, but no study has tested the blend for sleep or for anything else. As of October 2026 no licensed pharmacy may compound ipamorelin, so the ipamorelin half of any blend has no legal source. Sermorelin alone can be prescribed, and even its sleep benefit is unproven: no sermorelin trial has measured sleep objectively, and GHRH impaired sleep in studies of young women.

+−Is CJC-1295 legal in the US?

It is not legal for a pharmacy to compound it. CJC-1295 has never been an approved drug; FDA placed it in Category 2 in 2023; its advisory committee voted against every form, with and without DAC, in December 2024; and FDA now lists it as nominated but withdrawn, which gives no basis for compounding. Ipamorelin is in the same position after a committee vote against it in October 2024. Vials sold for research use are unapproved drugs, whatever the label says.

Sources

1. StudySteiger A et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 1992;56:566-73. (1992)
2. StudyMarshall L et al. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J Clin Endocrinol Metab 1996;81:1009-13. (1996)
3. StudyGuldner J, Schier T, Friess E, Colla M, Holsboer F, Steiger A. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging 1997;18:491-5. (1997)
4. StudyMathias S et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology 2007;32:1021-7. (2007)
5. StudyIonescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-7. (2006)
6. StudyKluge M et al. Ghrelin increases slow wave sleep and stage 2 sleep and decreases stage 1 sleep and REM sleep in elderly men but does not affect sleep in elderly women. Psychoneuroendocrinology 2010;35:297-304. (2010)
7. StudyFrieboes RM et al. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology 2004;29:851-60. (2004)
8. GuidelineEdinger JD et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2021;17:255-62. (2021)